3219-99-6

Basic information

• Product Name: epi-Doxycycline
• Synonyms: (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;6-Deoxy-6-epioxytetracycline;6-Epi Doxycycline;6-epi-Doxycycline;epi-Doxycycline;6-Epi Doxycycline, 65% (Contains Unknown Salts);Doxycycline Related Compound A (10 mg) (6-epidoxycycline);Doxycycline Related CoMpound A
• CAS NO: 3219-99-6
• Molecular Formula: C₂₂H₂₄N₂O₈
• Molecular Weight: 444.43456
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 3219-99-6.mol
• Article Data: 2

Chemical Properties

• Melting Point: >200°C (dec.)
• Boiling Point: 762.575°C at 760 mmHg
• Flash Point: 414.99°C
• Appearance: /
• Density: 1.639g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.737
• Storage Temp.: Hygroscopic, -20?C Freezer, Under Inert Atmosphere
• Solubility: Methanol (Slightly)
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: epi-Doxycycline(CAS DataBase Reference)
• NIST Chemistry Reference: epi-Doxycycline(3219-99-6)
• EPA Substance Registry System: epi-Doxycycline(3219-99-6)

Safety Data

• Hazardous Substances Data: 3219-99-6(Hazardous Substances Data)

Usage

Description

epi-Doxycycline is a decomposition product of Doxycycline, a broad-spectrum antibiotic. It is a dark yellow solid with unique chemical properties.

Uses

Used in Pharmaceutical Industry:
epi-Doxycycline is used as a pharmaceutical ingredient for its potential therapeutic applications. As a decomposition product of Doxycycline, it may possess distinct properties that can be utilized in the development of new drugs or drug formulations.
Used in Research and Development:
epi-Doxycycline serves as a valuable compound in research and development for studying the decomposition process of Doxycycline and understanding its chemical properties. This knowledge can contribute to the improvement of drug stability and the discovery of new pharmaceutical compounds.

InChI:InChI=1/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10-,14?,15+,17+,22+/m1/s1

Upstream product

• 3963-95-9 methacycline hydrochloride 

Relevant articles and documents

Ligand effects in the hydrogenation of methacycline to doxycycline and epi-doxycycline catalysed by rhodium complexes molecular structure of the key catalyst [closo-3,3-(η2,3-c7h7ch2)-3,1,2-rhc2b9h11]

The catalytic reduction of the exocyclic methylene group of methacycline (A) leads to the formation of two diastereoisomers, doxycycline (B, the α-epimer) and 6-epi-doxycycline (C, the β-epimer), with a selectivity which markedly depends on the nature of hydrocarbon and carborane ligands of closo-(π-cyclodienyl)rhodacarborane catalysts. Neutral norbornadienyl complexes with unsubstituted carborane ligands [closo-3,3-(η2,3-C7H7CH2)-3,1,2-RhC2B9H11] (1) and [closo-2,2-(η2,3-C7H7CH2)-2,1,7-RhC2B9H11] (7) are more active and afford higher selectivity in the formation of doxycycline than those having mono-or di-substituents at the carborane cage, [closo-3,3-(cyclodienyl)-1-R-2-R′-3,1,2-RhC2B9H9] (R = H, R′ = Me, PhCH2; R = R′ = Me; cyclodienyl = η2,3-C7H7CH2 or η-C10H13) as well as those from the closely related series of η5-cyclopentadienyl complexes [(η2,3-C7H7CH2)Rh(η5-C5Rn)]+PF-6 (Rn = H5, Me5, or H2-1,2,4-Ph3). Mechanistic aspects of the hydrogenation reaction of methacycline are sketched. The results of the X-ray diffraction study of the best catalyst 1 are reported.